How we grade.
PepTrack exists to let you understand peptides honestly — which means being just as clear about how we judge them as about the verdicts themselves. Here’s the whole rubric: the evidence scale, the regulatory taxonomy, what every dose figure rests on, and how the catalog is sourced and checked.
Every compound gets one grade for how good the evidence is — independent of whether it’s legal or popular. The grade reflects the strongest honest read of the human data, not the loudest marketing claim.
Randomized controlled trials at scale, plus a regulator’s sign-off. The strongest evidence a compound can carry — real efficacy and safety data, not inference.
There is genuine signal in people, but the compound isn’t FDA-approved for this use. Expect gaps in trial size, duration, or independent replication.
Preliminary, conflicting, or single-study human evidence — promising but not yet convincing. Currently empty: we don’t round weak evidence up to look stronger than it is.
Mechanism and rodent results, but no human efficacy data. Any human dose is an extrapolation, and the gap between a mouse and a person is wide.
A plausible biological story and user reports, but no controlled human evidence. The burden of proof is unmet — treat claims as hypotheses.
Why there’s no padding at C. A scale is only useful if the middle means something. We won’t promote animal data to “mixed human evidence” to fill a gap — if nothing earns a C, the row stays empty.
Legal status is tracked separately from evidence, because the two come apart constantly. The single most important thing to internalize:
Removed from Category 2 ≠ legal to compound ≠ FDA-approved.
Cleared by the FDA for a specific indication. The only tier where “approved” means what people think it means.
In active clinical development — real trials, no approval yet. Not lawfully sold as a finished drug.
Taken off the FDA’s interim compounding list, awaiting committee review. Removal is not endorsement — and not the same as legal to compound.
Flagged by the FDA as posing significant safety risks for compounding. A caution, not a clearance.
Sold “for research,” used off-label by people. No regulatory basis; quality and identity are unverified.
Prohibited in sport (WADA) or otherwise restricted. Listed plainly, with the source.
Numbers carry a tag so you never mistake a forum protocol for a label. Reconstitution examples are illustrative arithmetic, never a recommendation.
Each monograph is distilled from a research dossier of 584 de-duplicated sources across four research iterations, adversarially verified against primary sources — FDA dockets, DailyMed labels, ClinicalTrials.gov, and the peer-reviewed literature. Where sources disagree, we say so rather than picking the flattering one.
This field moves monthly. Everything is dated, and every monograph asks you to re-verify regulatory and dosing claims against the primary source before acting. Catalog last reviewed June 2026.
PepTrack is an educational, harm-reduction reference. It never tells you what to take, it isn’t a substitute for a clinician, and the interaction checker surfaces shared-mechanism and additive-load patterns — not a full drug-interaction database. Honest about the limits is still honest.
Not medical or legal advice. Re-verify against primary sources (FDA docket FDA-2025-N-6895, DailyMed, ClinicalTrials.gov) before acting.